ライフサイエンスコーパス: chronic viral hepatitis

1 tly increased in humans and chimpanzees with chronic viral hepatitis.

2 d recombinant IFN-alpha for the treatment of chronic viral hepatitis.

3 ion of immune responses to viral antigens in chronic viral hepatitis.

4 apeutic targets for this most severe form of chronic viral hepatitis.

5 .9%-100%) to those from source patients with chronic viral hepatitis.

6 is would have great therapeutic potential in chronic viral hepatitis.

7 nts with chronic NALD, but not in those with chronic viral hepatitis.

8 mage from a combination of alcohol abuse and chronic viral hepatitis.

9 Hepatitis D is the most severe form of chronic viral hepatitis.

10 ciated with more aggressive liver disease in chronic viral hepatitis.

11 o the cause and clinical course of acute and chronic viral hepatitis.

12 irrhosis, primary sclerosing cholangitis, or chronic viral hepatitis.

13 ring the same period, but had no evidence of chronic viral hepatitis.

14 ced hepatocellular carcinoma with or without chronic viral hepatitis.

15 ive agents in renal transplant patients with chronic viral hepatitis.

16 or challenges for modeling HBV infection and chronic viral hepatitis.

17 tudied zoonotic virus causing both acute and chronic viral hepatitis.

18 osis have less HSB, compared to patient with chronic viral hepatitis.

19 nsible for the most severe form of acute and chronic viral hepatitis.

20 TE concerning liver biopsy in children with chronic viral hepatitis.

21 ed patients with significant alcohol use and chronic viral hepatitis.

22 various SL metabolites in 406 patients with chronic viral hepatitis, 203 infected with genotype 1 he

23 was significantly greater among persons with chronic viral hepatitis (69% of cases) and those prescri

24 Chronic viral hepatitis accounts for >80% of liver-relat

25 ng 186,395 patients hospitalized with either chronic viral hepatitis, alcoholism, cirrhosis, or any c

26 isk of hepatocellular carcinoma was 34.4 for chronic viral hepatitis alone, 2.4 for alcoholism alone,

27 Chronic viral hepatitis and alcohol remain leading cause

28 rospective study has analyzed simultaneously chronic viral hepatitis and alcoholism as risk factors f

29 isk of hepatocellular carcinoma was 27.3 for chronic viral hepatitis and alcoholism, 118.5 for chroni

30 etrospective analysis of 1,117 patients with chronic viral hepatitis and analyzed whether age, sex, r

31 ating several clinical conditions, including chronic viral hepatitis and chronic myeloproliferative a

32 ic viral hepatitis and alcoholism, 118.5 for chronic viral hepatitis and cirrhosis, 22.4 for alcoholi

33 FN-alpha is widely used for the treatment of chronic viral hepatitis and malignancies.

34 This finding has important implications for chronic viral hepatitis and other chronic progressive vi

35 Individuals with chronic viral hepatitis and other forms of liver disease

36 s and the morbidity and mortality related to chronic viral hepatitis and released its findings in a r

37 of morbidity and mortality worldwide due to chronic viral hepatitis and, more recently, from fatty l

38 erythematosus, in 15 (20%) of patients with chronic viral hepatitis, and in four (17%) of those with

39 erythematosus, 14 (50%) of 28 patients with chronic viral hepatitis, and nine (39%) of 23 patients w

40 C diseases, such as alcoholic liver disease, chronic viral hepatitis, and porphyria cutanea tarda.

41 study included 50 children, 5-18 years with chronic viral hepatitis B (HBV) or hepatitis C (HCV) who

42 he prognosis and management of patients with chronic viral hepatitis B and C depend on the amount and

43 definition of "normal liver function tests." Chronic viral hepatitis B and C remain important risk fa

44 Chronic viral hepatitis B constitutes a public health pr

45 The determinants of the direct cost of chronic viral hepatitis B management were identified usi

46 nvasive methods used to manage patients with chronic viral hepatitis B or C infection.

47 The cost of chronic viral hepatitis B treatment at CHU-YO is very hi

48 hepatocellular carcinoma among patients with chronic viral hepatitis been prospectively evaluated in

49 infection results in the most severe form of chronic viral hepatitis but currently lacks effective tr

50 hepatocellular carcinoma among patients with chronic viral hepatitis, but it is not a prerequisite fo

51 landscape of antiviral treatment options for chronic viral hepatitis C (CHC), shared clinical decisio

52 examined operational interventions along the chronic viral hepatitis care continuum, published in Eng

53 y improve engagement and retention along the chronic viral hepatitis care continuum.

54 During development of chronic viral hepatitis, CCL5 and CXCL10 regulate the cy

55 and T2DM (NAFLD-T2DM cohort) and those with chronic viral hepatitis (CVH) alongside FLD and T2DM (FL

56 Chronic viral hepatitis depends on the inability of the

57 s performed in 1309 women without history of chronic viral hepatitis enrolled from 10 US sites: 928 w

58 hepatitis is an uncommon but severe form of chronic viral hepatitis for which there is currently no

59 Chronic viral hepatitis frequently goes undetected until

60 ults in hepatitis D, the most severe form of chronic viral hepatitis, frequently leading to liver dec

61 To compare the chronic viral hepatitis group and the NALD group, we use

62 Our findings suggest that patients with chronic viral hepatitis have accelerated epigenetic agin

63 on, nonalcoholic fatty liver disease, and/or chronic viral hepatitis (hepatitis B and C), results in

64 Chronic viral hepatitis (hepatitis B and hepatitis C) in

65 s in the control group was alcohol in 16.3%, chronic viral hepatitis in 30.6%, autoimmune hepatitis i

66 hat IL-29 may have therapeutic value against chronic viral hepatitis in human patients.

67 (HEPB-HEPD) disease is the severest form of chronic viral hepatitis in humans and is characterized b

68 ive virus leading to the most severe form of chronic viral hepatitis in man.

69 In a nationwide study of patients with chronic viral hepatitis in Sweden, use of low-dose aspir

70 was created to assess the clinical impact of chronic viral hepatitis in the United States.

71 Our data suggest that chronic viral hepatitis is associated with a significant

72 The optimal management of chronic viral hepatitis is evolving rapidly.

73 virus (HBV) is the major causative factor of chronic viral hepatitis, liver cirrhosis, and hepatocell

74 ver failure, and the presence of co-existing chronic viral hepatitis may increase its severity.

75 ifferentiated AIH from disease controls (PBC+chronic viral hepatitis+metabolic dysfunction-associated

76 monstrated significant utility in monitoring chronic viral hepatitis, metabolic-associated steatotic

77 and EDN (P <.02) compared with patients with chronic viral hepatitis (n = 22), autoimmune hepatitis (

78 rs and included the following diagnosis: (i) Chronic Viral Hepatitis (n = 271), (ii) Cirrhosis (n = 2

79 dult patients who underwent liver biopsy for chronic viral hepatitis (n=19) or other chronic non-alco

80 To assess the impact of chronic viral hepatitis on host immune response, we anal

81 Participants with a history of chronic viral hepatitis or excessive alcohol consumption

82 >/=6 months while receiving ART, and without chronic viral hepatitis or other known causes of chronic

83 ng patients with HIV mono-infection, without chronic viral hepatitis or other known causes of chronic

84 ing patients with HIV monoinfection, without chronic viral hepatitis or other known causes of chronic

85 hlight the substantial US health burden from chronic viral hepatitis, particularly among persons born

86 In patients with chronic viral hepatitis, probable cirrhosis developed in

87 relevant to the observation that fibrosis in chronic viral hepatitis progresses less rapidly and that

88 sCD163 levels are increased in patients with chronic viral hepatitis, reflecting macrophage activatio

89 nalysed operational interventions to enhance chronic viral hepatitis testing, linkage to care, treatm

90 oth biochemical and histological evidence of chronic viral hepatitis, the extent of liver injury was

91 otoxicity may be more common in persons with chronic viral hepatitis, these data do not support withh

92 ociated liver disease, and 101 patients with chronic viral hepatitis were determined by 1 H NMR (nucl